Pulmonary artery denervation (PADN)

DEVICE2 trials

Sponsors

Nanjing First Hospital, Nanjing Medical University, Pulnovo Medical, Inc.

Conditions

Cardiovascular DiseasesHeart FailureHeart Failure With Mid Range Ejection FractionHeart Failure With Preserved Ejection FractionHeart Failure With Reduced Ejection FractionHypertensionPulmonary HypertensionVascular Diseases

Unknown Phase

Pulmonary Arteyr Denervation for HF Without PH

CompletedNCT06323512

Nanjing First Hospital, Nanjing Medical UniversityHeart Failure

Start: 2024-08-01End: 2025-05-01Updated: 2025-06-26

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Not yet recruitingNCT07214376

Pulnovo Medical, Inc.Cardiovascular Diseases, Heart Failure, Heart Failure With Mid Range Ejection Fraction +5

Start: 2026-04-01End: 2031-12-31Target: 750Updated: 2026-03-12

Related Papers

Pulmonary artery denervation improves left ventricular diastolic function in patients with isolated post-capillary pulmonary hypertension secondary to heart failure with preserved ejection fraction: a safety and proof-of-principle cohort study.

2026-03-19